"Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial"
作者全名："Li, Jian; Zhang, Xinhua; Zhou, Yongjian; Zhang, Jun; Zhou, Ye; Wang, Ming; Wu, Xin; Deng, Yanhong; Huang, Zhao; Dong, Juan; Shen, Lin"
作者地址："Peking Univ Canc Hosp & Inst, Beijing, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China; Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China; Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China; Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China; Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China"
通信作者：
来源：JOURNAL OF CLINICAL ONCOLOGY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001053772002847
JCR分区：Q1
影响因子：42.1
年份：2023
卷号：41
期号：16
开始页：
结束页：
文献类型：Meeting Abstract
关键词：
摘要：
基金机构："Zai Lab (Shanghai) Co., Ltd."
基金资助正文："Zai Lab (Shanghai) Co., Ltd."
